Our previous study confirmed that low CPT1C expression plays a crucial role in RS and further identified CPT1C as a novel biomarker and key regulator of cancer cell senescence through mitochondria-associated metabolic reprogramming [2]. The gene discussed is CPT1C; the disease is cancer.